 |
 |
 |
 |
 |
|
 |
 |
 |
Express Plus Pharmacokinetics
The Express Plus ADME assays are screening assays with fixed protocols, useful for identifying promising drug-like leads at an early stage of drug discovery. On this page are listed those in vivo Express Plus assays that provide information on pharmacokinetics and bioavailability in different preclinical species. At the bottom of the page is a list of Assay Data Sheets, each of which summarizes one assay protocol, for our entire portfolio of Express Plus assays. Each of these assays is also available as a Custom assay, meaning that the protocol can be modified with conditions more appropriate for a particular test compound, additional bioanalytical rigor, etc.
| Catalog No. | Description | USD per Compound |
|---|---|---|
| OS021 | Express Plus ADME In Vivo Sales Order and Sample Submittal Form | |
| EA807 |
Mouse Exposure and/or Bioavailability
|
$5423 $3306 $2759 |
| EA808 |
Rat Exposure and/or Bioavailability
|
$4455 $2996 $2573 |
| EA810 |
Dog Exposure and/or Bioavailability
|
$10515 $9915 |
| EA812 |
Dog Exposure and/or Bioavailability Non-crossover
|
$11215 $10815 |
| EA813 | ABT Exposure in Rats | $4455 |
| EA982 | Formulation Assessment | $700 |
Why use an Express Plus Assay?
- Because there is no minimum compound requirement and you get significant discounts for multiple compounds
- Because you get a value added report for a low price
- Because you will receive your assay results in 10 working days or less
- Because you get the same well validated test systems for Express Plus assays as you would for our NDA-enabling studies
- Because you can rely on the quality of our data
Please note the following for in vivo assays:
- The price for cassette dosing is applicable only if one analytical method and one single injection can be used for the determination of all test compounds.
- One hour formulation prep cost has been included in the study price. Additional time required for formulation preparation will be charged at $200.00 per hour.
- The timeline for these studies is ten (10) business days from protocol signoff and test compound receipt, except for the dog exposure assay.
- The assay results are issued in Basic Report format and delivered via our secure website.
Related Literature
This assay is used to determine the solubility of a test compound at room temperature in phosphate buffer at pH 7.4.
Click Here to Download
This assay is used to determine the LogD of a test compound at pH 7.4 using the shake-flask method.
Click Here to Download
This assay is used to determine the stability of a test compound in whole blood or plasma from mouse, rat, rabbit, dog, monkey, or human.
Click Here to Download
This assay is used to determine the chemical stability of a test compound in buffer.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral direction.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral and basolateral- to-apical direction.
Click Here to Download
This assay is used to determine the blood-brain barrier (BBB) penetration potential of a test compound using MDR1-MDCK cell monolayers.
Click Here to Download
This assay is used to determine the P-gp interaction with a test compound using MDR1-MDCK cell monolayers in both the presence and absence of a P-gp inhibitor.
Click Here to Download
This assay is used to screen for inhibition of P-gp by a test compound, by measuring its effect on the bidirectional permeability of a P-gp substrate through Caco-2 cell monolayers.
Click Here to Download
This assay is used to identify active uptake of a test compound by PepT1, using the Caco-2 cell monolayer system.
Click Here to Download
This assay is used to determine the P-gp interaction with a test compound using CellPort™ CPT-B1 BCRP-knockdown cell monolayers in both the presence and the absence of a P-gp inhibitor.
Click Here to Download
This assay is used to determine the BCRP interaction with a test compound using CellPort™ CPT-B1 BCRP-knockdown cell monolayers and wild-type Caco-2 cell monolayers.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with pooled human liver microsomes in the presence of NADPH.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with pooled rat liver microsomes in the presence of NADPH.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with pooled mouse liver microsomes in the presence of NADPH.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with pooled primate liver microsomes in the presence of NADPH.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with pooled dog liver microsomes in the presence of NADPH.
Click Here to Download
This assay uses fluorogenic substrates to determine the potency with which a test compound inhibits recombinant human cytochrome P450 (CYP) enzymes.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with liver S9 fraction (mouse, rat, dog, monkey, or human) in the presence of cofactors.
Click Here to Download
This assay is used to determine the percent remaining and intrinsic clearance of a test compound incubated with cryopreserved hepatocytes (mouse, rat, dog, monkey, or human).
Click Here to Download
This assay is used to screen for reversible inhibition of individual cytochrome P450 (CYP) enzymes by a single concentration of a test compound.
Click Here to Download
This assay is used to determine the IC50 for reversible inhibition of individual cytochrome P450 (CYP) enzymes by a test compound.
Click Here to Download
This assay is used to screen for time-dependent inhibition of individual cytochrome P450 (CYP) enzymes by a test compound before and after pre-incubation with NADPH.
Click Here to Download
This assay is used to screen for time-dependent inhibition of individual cytochrome P450 (CYP) enzymes by a test compound after pre-incubation with and without NADPH.
Click Here to Download
This assay is used to assess the potential of a test compound to inhibit individual human UDP-glucuronosyltransferase (UGT) isoforms.
Click Here to Download
This assay is used to detect glucuronidation of a test compound after incubation with human liver microsomes in the presence of UDPGA.
Click Here to Download
This assay is used to detect a glutathione conjugate of a test compound, due to formation of a reactive metabolite, after incubation with human liver microsomes in the presence of NADPH and GSH.
Click Here to Download
This screening assay is used to identify the CYP(s) involved in the metabolism of a test compound, through the use of CYP-specific Supersomes.
Click Here to Download
This screening assay is used to identify the CYP(s) involved in the metabolism of a test compound, through the use of human liver microsomes and CYP-specific chemical inhibitors.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to human plasma proteins.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to rat plasma proteins.
Click Here to Download
This assay is used to determine the unbound fraction of test compound in a rat brain homogenate via equilibrium dialysis.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to mouse plasma proteins.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to primate plasma proteins.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to dog plasma proteins.
Click Here to Download
This assay is used to determine the blood-to-plasma partition coefficient of a test compound in mice, rats, and humans in vitro.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay is used to determine the bioavailability / exposure of a test compound in dogs after two routes of administration (non-crossover).
Click Here to Download
This screening assay uses the general CYP inhibitor, 1-aminobenzotriazole (ABT), to determine the role of absorption vs. first-pass metabolism in limiting the systemic exposure of a test compound in rats.
Click Here to Download
This assay is used to develop dose vehicle(s) for a test compound, as a solution or suspension prior to in vivo pharmacokinetic testing.
Click Here to Download
Brochures
A quick and cost-effective way to distinguish between poor absorption and rapid first-pass metabolism for compounds with poor oral bioavailability
Click Here to Download
In vitro, in situ, and in vivo models to assess brain penetration potential
Click Here to Download
Determination of exposure and bioavailability in preclinical species (rodents to primates)
Click Here to Download